4 Jan 2017 07:00
e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Directors' Dealings and Issue of Equity
Oxford and Newcastle, UK, 4 January 2017 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 3 January 2017 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 36,917 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") at a price of 7.45 pence per share. The subscription monies paid for the New Ordinary Shares represent 50% of Professor Jones' Non-Executive Director fees net of tax paid during the period from 1 October 2016 to 31 December 2016.
Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on 10 January 2017. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.
Following Admission, Professor Jones will be interested in a total of 107,497 ordinary shares of 0.1p in the Company, representing approximately 0.04% of the Company's issued share capital.
Following Admission the total number of ordinary shares in the Company with voting rights in issue will be 268,426,042. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
The Company previously announced that on 5 October 2016 Professor Jones entered into a binding contractual arrangement with the Company under which he agreed, with effect from1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-Therapeutics' ordinary shares.
The new shares will be issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid will be the average of the closing mid-market price for the five business days prior to the date of issue. The terms pursuant to which Professor Jones will purchase the shares are fixed and he has irrevocably committed to such terms.
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Ends-
Contacts:
e-Therapeutics plc Iain Ross, Chairman Steve Medlicott, Finance Director
| Tel: +44 (0) 1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Michael Meade / Freddie Barnfield(Corporate Finance) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
Instinctif Partners Melanie Toyne Sewell / Jayne Crook | Tel: +44 (0) 207 457 2020 Email: e-therapeutics@instinctif.com |
About e-Therapeutics plc
e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology. The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery.
e-Therapeutics has a variety of preclinical stage assets, including ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals.
The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk.
E-therapeutics (ETX)